ArticleDiabetes, obesity & metabolism2025
Plasma LEAP2 concentration is associated with energy intake and postprandial insulin increase depending on meal size but not weight status in men.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma LEAP2 concentration is associated with energy intake and postprandial insulin increase depending on meal size but not weight status in men.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsWhile LEAP2 is increasingly recognized as an appetite-regulating hormone, its role in meal regulation and the dynamics of postprandial LEAP2 concentrations remain poorly understood in humans. The aim of the study was to (1) assess postprandial LEAP2 concentrations following a recommended-energy breakfast, exploring potential association with voluntary energy intake and modulation by weight status and (2) to examine the interplay between postprandial LEAP2 and insulin concentrations. MATERIALS AND
methodsEighty-four men with normal weight (NW) and 48 with overweight or obesity (OW/OB) received a test meal; pre- and postprandial LEAP2 and insulin concentrations were assessed. Energy intake was calculated by multiplying the weight of the food items consumed by their energy content according to their label.
resultsFasting LEAP2 was positively associated with glycaemia in participants with NW [Beta (95% CI): 0.289 (0.058, 0.520), p = 0.015] but not with OW/OB. Sixty-seven participants consumed the entire test meal (CMC, complete meal consumption); the rest consumed only part (PMC, partial meal consumption). Postprandial LEAP2 concentration was higher in the PMC (p = 0.017) than in the CMC group and in participants with OW/OB (p = 0.046). Pre (p = 0.027) and postprandial (p = 0.031) LEAP2 was inversely related to ingested calories, but only in PMC and independent of weight status. Postprandial insulin increase (p < 0.001) depended on LEAP2 only in CMC (p = 0.017) and was independent of weight status.
conclusionsThe relationship of LEAP2 with energy intake and postprandial insulin increase is influenced by meal size but not weight status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.